Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
出版年份 2011 全文链接
标题
Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
作者
关键词
-
出版物
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 91, Issue 1, Pages 101-108
出版商
Springer Nature
发表日期
2011-12-01
DOI
10.1038/clpt.2011.275
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Circulating Tumor Cells as Biomarkers in Prostate Cancer
- (2011) D. C. Danila et al. CLINICAL CANCER RESEARCH
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
- (2011) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature
- (2011) Guru Sonpavde et al. EUROPEAN UROLOGY
- Flushing Oral Oncology Drugs Down the Toilet
- (2011) Mark J. Ratain JOURNAL OF CLINICAL ONCOLOGY
- Expanding Treatment Options for Metastatic Prostate Cancer
- (2011) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
- (2011) Emma Hörnberg et al. PLoS One
- PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer
- (2010) Tarek A. Bismar et al. BJU INTERNATIONAL
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids
- (2010) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to G. Attard et al
- (2010) Charles J. Ryan JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy
- (2009) Juan Morote et al. BJU INTERNATIONAL
- Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
- (2009) Peyman Hadji CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
- (2009) Prateek Mendiratta et al. JOURNAL OF CLINICAL ONCOLOGY
- New Developments in the Medical Management of Prostate Cancer
- (2009) Manish Kohli et al. MAYO CLINIC PROCEEDINGS
- Is PTEN loss associated with clinical outcome measures in human prostate cancer?
- (2008) P McCall et al. BRITISH JOURNAL OF CANCER
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor inactivation contributes to antitumor efficacy of 17 -hydroxylase/17,20-lyase inhibitor 3 -hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
- (2008) T. Vasaitis et al. MOLECULAR CANCER THERAPEUTICS
- Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure
- (2007) Carsten Jagusch et al. BIOORGANIC & MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started